In breast cancer, Zhang et al. revealed that HK2 enhances glycolysis through the ROS/PI3K/AKT pathway, and inhibiting HK2 lowered ROS levels, improving the efficacy of cancer treatments 168. Here, AKT1 is linked to cancer.